O
Otto C. Boerman
Researcher at Radboud University Nijmegen
Publications - 358
Citations - 17532
Otto C. Boerman is an academic researcher from Radboud University Nijmegen. The author has contributed to research in topics: Radioimmunotherapy & In vivo. The author has an hindex of 66, co-authored 355 publications receiving 15882 citations. Previous affiliations of Otto C. Boerman include Radboud University Nijmegen Medical Centre.
Papers
More filters
Journal ArticleDOI
Predicting IGF-1R Therapy Response in Bone Sarcomas: Immuno-SPECT Imaging with Radiolabeled R1507.
Emmy D.G. Fleuren,Yvonne M.H. Versleijen-Jonkers,Addy C.M. van de Luijtgaarden,Janneke D.M. Molkenboer-Kuenen,Sandra Heskamp,Melissa H.S. Roeffen,Hanneke W. M. van Laarhoven,Peter J. Houghton,Wim J.G. Oyen,Otto C. Boerman,Winette T. A. van der Graaf +10 more
TL;DR: Indium-111–labeled R1507 immuno-SPECT is an excellent method to visualize membranous IGF-1R expression and target accessibility in vivo in human bone sarcoma xenografts and may serve as an independent marker to predict IGF- 1R therapy (R1507) response in bone Sarcoma patients.
Journal ArticleDOI
Experimental radioimmunotherapy of small peritoneal metastases of colorectal origin
Manuel J. Koppe,Annemieke C. Soede,Wikke Pels,Wim J.G. Oyen,David M. Goldenberg,Robert P. Bleichrodt,Otto C. Boerman +6 more
TL;DR: Intraperitoneal radioimmunotherapy using 131I‐labeled MN‐14 delays significantly the outgrowth of peritoneal LS174T metastases, even at relatively low activity doses.
Journal ArticleDOI
Anti-CEA antibody fragments labeled with [(18)F]AlF for PET imaging of CEA-expressing tumors.
Susanne Lütje,Gerben M. Franssen,Robert M. Sharkey,Peter Laverman,Edmund A. Rossi,David M. Goldenberg,Wim J.G. Oyen,Otto C. Boerman,William J. McBride +8 more
TL;DR: This method was translated to preclinical PET imaging studies and showed feasibility of [(18)F]AlF-fluorinated hMN-14-Fab', [(18f]Alf-hMN- 14-Fab-AD2, and [(18F] alF-hmann14-diabody for microPET imaging of CEA-expressing colonic cancer.
Journal ArticleDOI
Radioimmunotherapy with [131I]cG250 in Patients with Metastasized Renal Cell Cancer: Dosimetric Analysis and Immunologic Response
Adrienne H. Brouwers,W.C.A.M. Buijs,Peter F.A. Mulders,Pieter H.M. De Mulder,Wim J.M. van den Broek,C. Mala,Egbert Oosterwijk,Otto C. Boerman,Frans H.M. Corstens,Wim J.G. Oyen +9 more
TL;DR: Dosimetric analysis did not adequately predict the degree of bone marrow toxicity, and according to the calculated absorbed dose in metastatic lesions, future radioimmunotherapy studies with radiolabeled cG250 should aim at treatment of small-volume disease or treatment in an adjuvant setting.
Journal ArticleDOI
Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy
Inja Waldhauer,Valeria Gonzalez-Nicolini,Anne Freimoser-Grundschober,Tapan K. Nayak,Linda Fahrni,Ralf Hosse,Danny Gerrits,Edwin J. W. Geven,Johannes Sam,Sabine Lang,Esther Bommer,Virginie Steinhart,Elisabeth Husar,Sara Colombetti,Erwin van Puijenbroek,Markus Neubauer,J. Mark Cline,Pradeep Garg,Gregory O. Dugan,Federica Cavallo,Gonzalo Acuna,Jehad Charo,Volker Teichgräber,Stefan Evers,Otto C. Boerman,Marina Bacac,Ekkehard Moessner,Pablo Umana,Christian Klein +28 more
TL;DR: Simlukafusp alfa (FAP-IL2v, RO6874281/RG7461) is an immunocytokine comprising an antibody against fibroblast activation protein α and an IL-2 variant with a retained affinity for IL 2Rβγ −> IL 2 as discussed by the authors.